Autor segons l'article: Pérez-Cantero A, Serrano DR, Navarro-Rodríguez P, Schätzlein AG, Uchegbu IF, Torrado JJ, Capilla J
Departament: Ciències Mèdiques Bàsiques
Autor/s de la URV: Capilla Luque, Javier / PÉREZ CANTERO, ALBA
Paraules clau: Supplementation Shiitake Resistance Posaconazole Oral delivery Necrosis-factor-alpha Molecular envelope technology Lipid nanoparticles Lentinula edodes Lentinan Hexose-correlated compound Fungus Fumigatus Formulations Chitosan Aspergillosis Amphotericin b Ahcc® Ahcc (r)
Resum: Invasive pulmonary aspergillosis represents one of the most serious fungal infections among immunocompromised patients. In this study, we aimed to analyze the in vivo efficacy of prophylactic oral amphotericin B (AMB) encapsulated in modified chitosan-nanoparticles (Nanomerics' Molecular Envelope Technology (MET)) supplemented with a standardized extract of cultured Lentinula edodes mycelia (AHCC®) in a murine model of pulmonary aspergillosis. We determined fungal burden and survival of mice and additionally, we carried out a cytokine analysis in an attempt to understand the immunomodulation of the extract. Our results evidenced equivalent efficacy between orally administered AMB-MET and the intravenous liposomal AMB marketed formulation. Addition of the AHCC® supplement significantly improved efficacy in terms of burden reduction and survival increase of both oral and intravenous AMB therapies compared to the untreated control group. Moreover, a protective effect of the extract was observed in terms of weight loss. Regarding the cytokine profiles, the Th1 immune response was stimulated in treated animals when compared to the control group. This response was marked by an enhancement in the MCP-1, GM-CSF, VEGF, RANTES and IL-17 levels and a decrease in the IL-6, a biomarker related to the severity of the infection.
Àrees temàtiques: Pharmacology & pharmacy Pharmaceutical science Medicina ii Farmacia Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Biotecnología
Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
ISSN: 19994923
Adreça de correu electrònic de l'autor: javier.capilla@urv.cat
Identificador de l'autor: 0000-0002-0765-6403
Data d'alta del registre: 2023-02-18
Volum de revista: 11
Versió de l'article dipositat: info:eu-repo/semantics/publishedVersion
Enllaç font original: https://www.mdpi.com/1999-4923/11/9/456
Referència a l'article segons font original: Pharmaceutics. 11 (9):
Referència de l'ítem segons les normes APA: Pérez-Cantero A, Serrano DR, Navarro-Rodríguez P, Schätzlein AG, Uchegbu IF, Torrado JJ, Capilla J (2019). Increased Efficacy of Oral Fixed-Dose Combination of Amphotericin B and AHCC® Natural Adjuvant against Aspergillosis. Pharmaceutics, 11(9), -. DOI: 10.3390/pharmaceutics11090456
URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
DOI de l'article: 10.3390/pharmaceutics11090456
Entitat: Universitat Rovira i Virgili
Any de publicació de la revista: 2019
Tipus de publicació: Journal Publications